Table 1.
Patient characteristics of the discovery cohort divided by absence or presence of acute liver injury according to the British National Formulary 200937
| >50% ALT rise | No > 50% ALT rise | P‐value | |
|---|---|---|---|
| Number | 14 | 102 | |
| Median (IQR) age (years) | 28 (21‐32) | 37 (26‐48) | 0.03 |
| Median (IQR) weight (kg) | 62 (56‐71) | 70 (59‐80) | 0.27 |
| Number of females | 11 (79%) | 61 (55%) | 0.17 |
| Median (IQR) time from ingestion to treatment (h) | 6.7 (7.8‐10.7) | 7.2 (8.0‐10.0) | 0.63 |
| Number with ingestion to treatment <8hr | 8 (57%) | 65 (64%) | 0.63 |
| Median (IQR) ingested acetaminophen (mg/kg) | 332 (190‐393) | 222 (165‐313) | 0.06 |
| Number who ingested acetaminophen ≥16g | 9 (64%) | 44 (43%) | 0.14 |
| Median (IQR) admission alanine aminotransferase (U/L) | 24 (18‐82) | 18 (13‐26) | 0.04 |
| Median (IQR) peak alanine aminotransferase (U/L) | 154 (65‐909) | 18 (14‐27) | < 0.0001 |
| Median (IQR) admission INR | 1.0 (1.0‐1.2) | 1.0 (0.9‐1.0) | 0.01 |
| Median (IQR) peak INR | 1.4 (1.3‐1.6) | 1.1 (1.0‐1.2) | < 0.0001 |
| Median (IQR) admission billirubin (μmol/l) | 12 (7‐17) | 7 (5‐9) | 0.009 |
| Median (IQR) admission GGT (U/l) | 19 (12‐42) | 25 (16‐42) | 0.25 |
| Median (IQR) admission creatinine (μmol/l) | 69 (59‐81) | 65 (59‐74) | 0.44 |
| Median (IQR) peak creatinine (μmol/l) | 70 (59‐81) | 67 (60‐79) | 0.68 |
| Median (IQR) change in creatinine (%) | ‐5.4 (‐22.8‐3.1) | ‐6.0 (‐12.6‐1.7) | 0.46 |
| Alcohol ingested | 1 (7%) | 59 (58%) | < 0.0001 |
| Other drugs ingested | 9 (64%) | 67 (66%) | 0.92 |
| Nutritional deficiency | 2 (14%) | 17 (17%) | 0.82 |
| Debilitating disease | 0 (0%) | 2 (2%) | 0.60 |
| Chronic alcohol use | 0 (0%) | 44 (43%) | 0.002 |
| Identified as high risk | 2 (14%) | 57 (56%) | 0.004 |
| Number who received ondansetron | 11 (79%) | 46 (45%) | 0.02 |
| Number who received modified NAC | 7 (50%) | 57 (56%) | 0.68 |
P‐value for difference between groups was determined by Mann‐Whitney test or chi‐square test.